Almac Achieves Double Success at Business Award Ceremony
News Apr 01, 2014
Almac has announced the exceptional achievement of picking up two category awards at prestigious Belfast Telegraph Business Award gala ceremony in association with British Airways. The awards are in their 12th year and are the premier symbol in Northern Ireland of commercial, industrial and social enterprise achievements.
The winning “Excellence in Innovation” entry focussed on the development of our Antibody Drug Conjugation (ADC) offering provided by the Science’s biocatalysis group headed up by Professor Tom Moody. Almac has developed the innovative ADC science from the laboratory bench into successful, novel, commercial offerings that are now part of their existing business portfolio.
The trophy was presented by Kevin Traynor, Belfast Telegraph’s Digital Director to Dr William Watters, Isotope Chemistry Manager at Almac’s Sciences Business Unit. The other 2 finalists in this category were Core Systems and Randox Laboratories.
The “Excellence in Technology” award recognized the advances made by the Diagnostics team in relation to the recently announced DNA Damage Repair Deficiency (DDRD) research. This new technology offers significant advances in the treatment of cancer and has recently been the subject of a collaboration with US-based Genomic Health Inc to bring its benefits to patients worldwide.
The trophy was collected by Michael Sloan, VP Business Development for the Diagnostics Business Unit from Karen Blair, MD, Clever Fulton Rankin who sponsored the award. Other finalists in this category were PathXL and Taggled Ltd.
Alan Armstrong, CEO, Almac Group commented on receiving the honours: “We are delighted to receive these prestigious awards and is a tremendous tribute to the pioneering work carried out on a daily basis by our dedicated and talented teams here at Almac. It is especially pleasing to achieve recognition for our work within the context of such strong local competition and is testimony to the true innovation and technology that we pride ourselves on within the pharmaceutical and biotech industry.”